Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, said on Monday that it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to expand the approved use of its HIV treatments Tivicay (dolutegravir) and Dovato (dolutegravir/lamivudine) to younger children.
The recommendation for Tivicay includes use in term newborns from birth weighing at least 2kg, potentially making it the first second-generation integrase inhibitor available for eligible newborns in the European Union. Dovato has been recommended for a new dispersible tablet formulation for children aged at least three months and weighing between 6kg and 25kg, as well as an expanded indication for its existing tablet formulation.
If approved, Dovato could become the first single-tablet, two-drug HIV treatment option for eligible younger children in the EU.
The recommendations are supported by paediatric clinical studies and pharmacokinetic modelling, with safety and tolerability profiles consistent with those observed in older children and adults.
European Commission decisions on both applications are expected in the first quarter of 2027. A separate US application for Dovato's paediatric use is also under review, with a decision expected in the same quarter.
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Langhua Pharmaceutical passes US FDA's on-site inspection
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency